Advertisement

Selective chemodenervation with botulinum toxin in facial nerve disorders

  • Jon-Paul Pepper
    Correspondence
    Address reprint requests and correspondence: Jon-Paul Pepper, MD, Center for Facial Cosmetic Surgery, 19900 Haggerty Road, Suite 103, Livonia, MI 48152
    Affiliations
    Department of Otolaryngology, Head and Neck Surgery, University of Michigan Hospital and Health Systems, Ann Arbor, Michigan

    Center for Facial Cosmetic Surgery, University of Michigan, Livonia, Michigan
    Search for articles by this author
  • Jennifer C. Kim
    Affiliations
    Department of Otolaryngology, Head and Neck Surgery, University of Michigan Hospital and Health Systems, Ann Arbor, Michigan

    Center for Facial Cosmetic Surgery, University of Michigan, Livonia, Michigan
    Search for articles by this author
      Selective chemodenervation is an important adjunct in the management of several aspects of facial nerve paralysis and paresis. Herein, the authors describe the utility of chemodenervation in the treatment of the synkinesis and contralateral hyperkinesis often associated with facial nerve injury.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Operative Techniques in Otolaryngology-Head and Neck Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Scott A.B.
        • Rosenbaum A.
        • Collins C.C.
        Pharmacological weakening of extraocular muscle.
        Invest Ophtalmol. 1973; 12: 924
        • Clark R.P.
        • Berris C.E.
        Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis.
        Plast Reconstr Surg. 1989; 84: 353-355
        • May M.
        • Croxson G.R.
        • Klein S.R.
        Bell's palsy: management of sequelae using EMG rehabilitation, botulinum toxin, and surgery.
        Am J Otol. 1989; 10: 220-229
        • Roggenkämper P.
        • Laskawi R.
        • Damenz W.
        • et al.
        Involuntary lid closure caused by defective healing of facial paralysis and its treatment with botulinum toxin.
        Klin Monbl Augenheilkd. 1991; 198: 268-270
        • Chong P.N.
        • Ong B.
        • Chan R.
        Botulinum toxin in the treatment of facial dyskinesias.
        Ann Acad Med Singapore. 1991; 20: 223-227
        • Mehta R.P.
        • Hadlock T.A.
        Botulinum toxin and quality of life in patients with facial paralysis.
        Arch Facial Plast Surg. 2008; 10: 84-87
        • Sardesai M.G.
        • Moe K.
        Recent progress in facial paralysis: advances and obstacles.
        Curr Opin Otolaryngol Head Neck Surg. 2010; 18: 266-271
        • De Maio M.
        • Bento R.F.
        Botulinum toxin in facial palsy: an effective treatment for contralateral hyperkinesis.
        Plast Reconstr Surg. 2007; 120 (discussion 928): 917-927
        • Sahin S.
        • Yaman M.
        • Mungan S.O.
        • et al.
        What happens in the other eye?.
        J Clin Neurophysiol. 2009; 26: 454-457
        • Crumley R.L.
        Mechanisms of synkinesis.
        Laryngoscope. 1979; 89: 1847-1854
        • Yamada H.
        • Hato N.
        • Murakami S.
        • et al.
        Facial synkinesis after experimental compression of the facial nerve comparing intratemporal and extratemporal lesions.
        Laryngoscope. 2010; 120: 1022-1027
        • Husseman J.
        • Mehta R.P.
        Management of synkinesis.
        Facial Plast Surg. 2008; 24: 242-249
        • Blomstedt G.C.
        • Jääskeläinen J.E.
        • Pyykkö I.
        • et al.
        Recovery of the sutured facial nerve after removal of acoustic neuroma in patients with neurofibromatosis-2.
        Neurosurgery. 1994; 35: 364-368
        • Choi D.
        • Raisman G.
        After facial nerve damage, regenerating axons become aberrant throughout the length of the nerve and not only at the site of the lesion: an experimental study.
        Br J Neurosurg. 2004; 18: 45-48
        • Ross B.G.
        • Fradet G.
        • Nedzelski J.M.
        Development of a sensitive clinical facial grading system.
        Otolaryngol Head Neck Surg. 1996; 114: 380-386
        • Vrabec J.T.
        • Backous D.D.
        • Djalilian H.R.
        • et al.
        Facial nerve grading system 2.0.
        Otolaryngol Head Neck Surg. 2009; 140: 445-450
        • On A.Y.
        • Yaltirik H.P.
        • Kirazli Y.
        Agreement between clinical and electromyographic assessments during the course of peripheral facial paralysis.
        Clin Rehabil. 2007; 21: 344-350
        • Mehta R.P.
        • WernickRobinson M.
        • Hadlock T.A.
        Validation of the synkinesis assessment questionnaire.
        Laryngoscope. 2007; 117: 923-926
        • Bikhazi N.B.
        • Maas C.S.
        Refinement in the rehabilitation of the paralyzed face using botulinum toxin.
        Otolaryngol Head Neck Surg. 1997; 117: 303-307
        • Borodic G.
        • Bartley M.
        • Slattery W.
        • et al.
        Botulinum toxin for aberrant facial nerve regeneration: double-blind, placebo-controlled trial using subjective endpoints.
        Plast Reconstr Surg. 2005; 116: 36-43
        • Salles A.G.
        • Toledo P.N.
        • Ferreira M.C.
        Botulinum toxin injection in long-standing facial paralysis patients: improvement of facial symmetry observed up to 6 months.
        Aesthet Plast Surg. 2009; 33: 582-590
        • Brach J.S.
        • VanSwearingen J.M.
        Physical therapy for facial paralysis: a tailored treatment approach.
        Phys Ther. 1999; 79: 397-404
        • Hackett R.
        • Kam P.C.
        Botulinum toxin: pharmacology and clinical developments: a literature review.
        J Med Chem. 2007; 34: 333-345
        • Naumann M.
        • Albanese A.
        • Heinen F.
        • et al.
        Safety and efficacy of botulinum toxin type a following long-term use.
        Eur J Neurol. 2006; 13: 35-40
        • Coté T.R.
        • Mohan A.K.
        • Polder J.A.
        • et al.
        Botulinum toxin type a injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
        J Am Acad Dermatol. 2005; 53: 407-415
        • Ferreira M.C.
        • Salles A.G.
        • Gimenez R.
        • et al.
        Complications with the use of botulinum toxin type a in facial rejuvenation: report of 8 cases.
        Aesthet Plast Surg. 2004; 28: 441-444
        • Dressler D.
        • Eleopra R.
        Clinical use of non-A botulinum toxins: botulinum toxin type B.
        Neurotox Res. 2006; 9: 121-125
        • Guerrissi J.O.
        Selective myectomy for postparetic facial synkinesis.
        Plast Reconstr Surg. 1991; 87: 459-466
        • Dobie R.A.
        • Fisch U.
        Primary and revision surgery (selective neurectomy) for facial hyperkinesia.
        Arch Otolaryngol Head Neck Surg. 1986; 112: 154-163
        • Terzis J.K.
        • Karypidis D.
        Therapeutic strategies in post-facial paralysis synkinesis in adult patients.
        Plast Reconstr Surg. 2012; 129: 925e-939e